— An international team of experts certainly thinks so. Their new findings indicate that serum glial fibrillary acidic protein can predict worsening independent of relapse activity in multiple sclerosis.
A serum biomarker for disease progression in multiple sclerosis (MS) may be a game changer for research and, ultimately, for treatment of patients with the most devastating forms of the disease, indicate the results of a new study.
View Full Article on MEDPAGE TODAY published on 11 May 2023.
